• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:13:51 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXTC alert in real time by email
    SC 13G/A 1 greatpoint-nxtc123120a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    NextCure, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    65343E108

    (CUSIP Number)

     

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     


     

    CUSIP No.  65343E108
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Great Point Partners, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0%
    12
    TYPE OF REPORTING PERSON
     
    IA/OO

     


     

    CUSIP No.  65343E108
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Dr. Jeffrey R. Jay, M.D.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0%
    12
    TYPE OF REPORTING PERSON
     
    IN/HC

     


     

    CUSIP No.  65343E108
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Mr. Ortav Yehudai
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0%
    12
    TYPE OF REPORTING PERSON
     
    IN/HC

     


     

     

    CUSIP No. 65343E108
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    NextCure, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    9000 Virginia Manor Road, Suite 200

    Beltsville, Maryland 20705

    Item 2.(a) Names of Persons Filing:

    Great Point Partners, LLC

    Dr. Jeffrey R. Jay, M.D.

    Mr. Ortav Yehudai

     

    The Reporting Persons have entered into a Joint Filing Agreement, dated February 16, 2021, a copy of which is filed with this Schedule 13G/A as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

     

    Item 2.(b) Address of Principal Business Office:

    The address of the principal business office of each of the Reporting Persons is

     

    165 Mason Street, 3rd Floor

    Greenwich, CT 06830

     

    Item 2.(c) Citizenship:

    Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. Ortav Yehudai is a citizen of the United States.

      

    Item 2.(d) Title of Class of Securities

    Common Stock, par value $0.001 per share

     

    Item 2.(e) CUSIP No.:

    65343E108

     

    CUSIP No.  65343E108
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 65343E108
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    1. Great Point Partners, LLC

    (a) Amount beneficially owned: 0 

    (b) Percent of class: 0.0% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    2. Dr. Jeffrey R. Jay, M.D.

    (a) Amount beneficially owned: 0 

    (b) Percent of class: 0.0% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    3. Mr. Ortav Yehudai

    (a) Amount beneficially owned: 0 

    (b) Percent of class: 0.0% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0 

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    See Item 4.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 65343E108
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 16, 2021

     

     

     

     

    Great Point Partners, LLC

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D., as Senior Managing Member
           
     

    Dr. Jeffrey R. Jay, M.D.

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D.
           
     

    Mr. Ortav Yehudai

           
      By:  /s/ Mr. Ortav Yehudai
        Mr. Ortav Yehudai
           

     

     
    CUSIP No. 65343E108
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit A

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned hereby agree as follows:

     

    (i) Each of them is individually eligible to use the Schedule 13G/A to which this Exhibit is attached, and such Schedule 13G/A is filed on behalf of each of them; and

     

    (ii) Each of them is responsible for the timely filing of such Schedule 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

     

    Dated: February 16, 2021

     

     

    Great Point Partners, LLC

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D., as Senior Managing Member
           
     

    Dr. Jeffrey R. Jay, M.D.

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D.
           
     

    Mr. Ortav Yehudai

           
      By:  /s/ Mr. Ortav Yehudai
        Mr. Ortav Yehudai
    Get the next $NXTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXTC

    DatePrice TargetRatingAnalyst
    11/7/2025$18.00Neutral → Buy
    Ladenburg Thalmann
    11/4/2022Buy → Neutral
    Ladenburg Thalmann
    3/1/2022$16.00Buy
    Ladenburg Thalmann
    11/5/2021$30.00 → $14.00Buy
    Needham
    More analyst ratings

    $NXTC
    SEC Filings

    View All

    NextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - NextCure, Inc. (0001661059) (Filer)

    1/23/26 7:20:30 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - NextCure, Inc. (0001661059) (Filer)

    12/19/25 5:31:12 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by NextCure Inc.

    424B5 - NextCure, Inc. (0001661059) (Filer)

    12/19/25 5:29:54 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NextCure Provides Business Update

    SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a preliminary year-end 2025 cash position. SIM0505 (CDH6 ADC): Phase 1 dose escalation data expected in Q2 2026SIM0505 is a novel ADC directed to cadherin-6 (CDH6 ADC), which is overexpressed in several cancers with limited expression in healthy tissues. SIM0505 features a

    1/23/26 7:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

    BELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City on Wednesday, December 3rd, at 11:00 am ET. A live audio webcast will be available through the Investors section of the company's website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company

    11/20/25 8:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

    Extends cash runway into first half of 2027, beyond planned first half of 2026 proof of concept ("POC") data readouts of SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC)Led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome Asset Management in a private placement of common stock priced at the market BELTSVILLE, Md., Nov. 17, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced the closing of its previously announced private placement in public equity ("PIPE"). The PIPE was led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare F

    11/17/25 8:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NextCure upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded NextCure from Neutral to Buy and set a new price target of $18.00

    11/7/25 8:06:56 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded NextCure from Buy to Neutral

    11/4/22 1:03:13 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on NextCure with a new price target

    Ladenburg Thalmann initiated coverage of NextCure with a rating of Buy and set a new price target of $16.00

    3/1/22 7:18:07 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sr VP, General Counsel Shaw Kevin G.

    4 - NextCure, Inc. (0001661059) (Issuer)

    2/3/26 4:07:22 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sr VP, Dev. & Mfg. Kundu Sourav

    4 - NextCure, Inc. (0001661059) (Issuer)

    2/3/26 4:07:20 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President & CEO Richman Michael

    4 - NextCure, Inc. (0001661059) (Issuer)

    2/3/26 4:07:18 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Leadership Updates

    Live Leadership Updates

    View All

    NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

    BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4. "We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug c

    4/4/24 7:05:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

    BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board. As an accomplished translational tumor immunologist whose research is focused on the role immune cells play in tumor development, Dr. Coussens will support NextCure in its efforts to build and develop its proprietary pipeline of immunomedicines. "We are delighted to have Dr. Coussens join our Scientific Advisory Board, where she will leverage

    10/27/22 4:05:00 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

    BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update. “Our team has worked diligently throughout 2020 to advance our programs despite the difficult environment created by the COVID-19 pandemic. We are thrilled that Dr. Han Myint has recently joined NextCure as our Chief Medical Officer and we are poised to harness his expertise in oncology product development to further advance our product pipe

    3/4/21 4:05:00 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Financials

    Live finance-specific insights

    View All

    NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021

    BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a Virtual Oncology Pipeline Update Event at 4:30 p.m. ET on Monday, November 15, 2021. During the event, NextCure will provide an update on its oncology pipeline, including data presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. The event will also feature Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Directo

    11/1/21 8:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NextCure Inc.

    SC 13G/A - NextCure, Inc. (0001661059) (Subject)

    11/14/24 6:59:21 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NextCure Inc.

    SC 13G/A - NextCure, Inc. (0001661059) (Subject)

    11/13/24 4:06:36 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by NextCure Inc.

    SC 13G - NextCure, Inc. (0001661059) (Subject)

    6/27/24 4:47:26 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care